Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP, CHIEF FINANCIAL OFFICER | May 11, 2023 | May 15, 2023 |
| GERON CORPGERN · Entity 4989 | EVP, CHIEF FINANCIAL OFFICER | February 17, 2026 | February 19, 2026 |
| MOMENTA PHARMACEUTICALS INCMNTA · Entity 146313 | Chief Financial Officer | October 25, 2019 | October 30, 2019 |
| Verastem, Inc.VSTM · Entity 5242 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date May 11, 2023 · Filed May 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,610 |
Reported balance
After 2023-05-11 transaction · row 1
1 source rowRow 1 · 2023-05-11 · Sale · Disposed 949 · Balance 106,610 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 10, 2023. The sale does not represent a discretionary trade by the Reporting Person.
GERON CORP
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,500 |
Reported balance
After 2026-02-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-18 · Exercise / conversion · Acquired 27,500 · Balance 27,500 F1: Shares of common stock acquired upon the vesting of restricted stock units ("RSUs"). |
| Common StockSEC Table I · non-derivative | Direct | 17,645 |
Reported balance
After 2026-02-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-18 · Sale · Disposed 9,855 · Balance 17,645 F2: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the Reporting Person's applicable RSU agreement, and does not represent a discretionary sale by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-16 | Direct | 1,660,000 |
Reported balance
After 2026-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-17 · Grant · Acquired 1,660,000 · Balance 1,660,000 F3: The option vests in 48 equal monthly installments commencing on March 17, 2026, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 82,500 |
Reported balance
After 2026-02-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-18 · Exercise / conversion · Disposed 27,500 · Balance 82,500 F4: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F5: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock acquired upon the vesting of restricted stock units ("RSUs").
F2: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the Reporting Person's applicable RSU agreement, and does not represent a discretionary sale by the Reporting Person.
F3: The option vests in 48 equal monthly installments commencing on March 17, 2026, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date.
F4: Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F5: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date.
MOMENTA PHARMACEUTICALS INC
Report date October 25, 2019 · Filed October 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,813 |
Reported balance
After 2019-10-25 transaction · row 1
1 source rowRow 1 · 2019-10-25 · Sale · Disposed 6,802 · Balance 6,813 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan.
Verastem, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,666 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 36,000 · Balance 52,666 F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2019 Filed Feb 19, 2019 21:55 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 703 | $13.10 | $9,209.30 |
DisclosureSEC source: 0001179110-19-002091 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,526 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 21:28 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 1,410 | $12.70 | $17,907.00 |
DisclosureSEC source: 0001179110-19-001909 · edgar.xml · nonDerivative · entry 2 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,229 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:28 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 4,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001909 · edgar.xml · derivative · entry 3 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,870 Underlying: Common Stock · 4,870 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:28 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 4,870 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-001909 · edgar.xml · nonDerivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:44 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 97,000 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001179110-19-001837 · edgar.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 Underlying: Common Stock · 97,000 shares Expires 2029-02-11 F1 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated. F2 · derivative.exercise_date: The stock option will vest and become exercisable with respect to 24,250 shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. All vesting is subject to Michelle Robertson's continued service to the Company through the applicable vesting date. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 22:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-012297 · edgar.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock. F2 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F2 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.